Sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) have shown benefits that extend beyond blood sugar lowering to weight loss, reduced blood pressure, and improved outcomes in heart failure and chronic kidney disease. This evidence concerns the gene SLC5A2 and heart failure.